Needham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q

Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance

BMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.

Somaiya comments, "We are maintaining our Market... More

Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within'

Following its 'kitchen sink' HCV guidance and subsequent 9% sell-off, the urgency for Gilead Sciences (NASDAQ: GILD) to make an acquisition continues to intensify. On the call, the company essentially admitted that it cannot grow over the next few years without a... More

Gilead Sciences (GILD) Pressured on Market Open, Shares Down 10%

Gilead Sciences (NASDAQ: GILD) Pressured on Market Open, Shares Down 10%

Gilead Sciences (GILD) PT Lowered to $83 at Jefferies

Jefferies lowered its price target on Gilead Sciences (NASDAQ: GILD) to $83.00 (from $93.00) while maintaining a Buy rating.

Analyst Dr. Brian Abrahams comments "Accumulating challenges to HCV franchise finally come to a head, with solid 4Q overshadowed by guidance dramatically lower than consensus. Low... More

Gilead (GILD) PT Drops to $87 at Baird on 2017 Guidance

Baird analyst Brian Skorney maintains Outperform rating, but lowers price target on Gilead Sciences (NASDAQ: GILD) to $87 (from $100), as the company provided fiscal year revenue guidance well below consensus.

Skorney notes, 2017 guidance likely to bottom out stock. We believe investors were expecting... More

Piper Jaffray On Gilead (GILD) - It Stinks But If You Hold Your Nose It's Not That Bad

Piper Jaffray lowered its price target on Gilead Sciences (NASDAQ: GILD) to $95.00 (from $102.00) while maintaining a Overweight rating.

Analyst Dr. Joshua Schimmer comments "It stinks--but if you hold your nose, it's not that bad: Most are frustrated by GILD's "evasive maneuvering" when asked... More

Gilead Sciences (GILD) PT Lowered to $79 at Credit Suisse, Says M&A Is Upside Driver From Here

Credit Suisse lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $93.00) while maintaining a Outperform rating.

Analyst Alethia Young comments "Growth likely through M&A (or deployment of cash) has to be the core of our thesis from here.... More

Welsl Fargo Lowering PT Range On Gilead (GILD)

Wells Fargo maintains Market Perform Gilead Sciences (NASDAQ: GILD)

The analyst is lower the valuation range for GILD from $77-82 to $63-$68, commenting "Medicaid patients could provide stability in 2017, according to GILD. Offsetting, partially, declining HCV product sales is growth of non-HIV... More

Gilead Sciences (GILD) PT Lowered to $77 at Morgan Stanley

Morgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $77.00 (from $85.00) while maintaining a Equalweight rating.

Analyst Matt Harrison comments "4Q16 beat, but 2017 rev guide was 15% below cons and 9% below our Street low ests. HCV (-30% vs cons;... More

Citi Downgrades Gilead Sciences (GILD) to Neutral

Citi downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Neutral with a price target of $76.00 (from $87.00).

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $73.13 yesterday.

After-Hours Stock Movers 02/07: (COHR) (MCHP) (JIVE) Higher; (USNA) (DRYS) (ZG) (GILD) Lower (more...)

Today's After-Hours Movers:

USANA Health Sciences (NYSE: USNA) 20.1% LOWER; reported Q4 EPS of $0.87, $0.07 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $252.9 million versus the consensus estimate of $253.52 million. GUIDANCE: USANA Health Sciences sees FY2017 EPS of $3.80-$4.10, versus the consensus of $4.47. USANA Health Sciences sees FY2017 revenue of $1.04-1.07 million, versus the consensus of $1.11 million.

Coherent, Inc. (NASDAQ: COHR) 13.5% HIGHER; reported Q2 Non-GAAP EPS of $2.57, $0.81 better than the analyst estimate of... More

Gilead Sciences (GILD) Raises Quarterly Dividend 10.6% to $0.52; 2.8% Yield

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.52 per share, or $2.08 annualized. This is a 10.6% increase from the prior dividend of $0.47.

The dividend will be payable on March 30, 2017, to stockholders of record on March 16, 2017, with an ex-dividend date of March 14,... More

Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $2.70, $0.09 better than the analyst estimate of $2.61. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.15 billion.

Full... More

Gilead (GILD) volatility bid up into Q4 and outlook

Gilead Sciences (NASDAQ: GILD) February weekly call option implied volatility is at 56, February is at 35, March is at 24, compared to its 52-week range of 19 to 36 into the expected release of Q4 results.

Gilead (GILD) call put ratio 1 call to 1.4 put into Q4

Gilead Sciences (NASDAQ: GILD) February weekly call option implied volatility is at 51, February is at 35, March is at 24, compared to its 52-week range of 19 to 36 into the expected release of Q4 results on February 7.

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

By Ben Hirschler

LONDON (Reuters) - Emma Walmsley, GlaxoSmithKline's (NYSE: GSK) incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

Just four days before Walmsley moves into the top job on April 1, U.S. regulators could approve the first substitutable generic version of GSK's inhaled lung drug Advair, which has raked in more than a $1 billion in sales every year since 2001.

Walmsley is expected to formally present her strategic vision for the... More

Wall Street slips as energy shares, oil prices drop

By Lewis Krauskopf

(Reuters) - U.S. stocks slipped on Monday, led by the energy sector as oil prices dropped, while investors awaited the next run of major earnings reports and sought further clarity on President Donald Trump's economic policies.

The benchmark S&P 500 receded after climbing close to a record high on Friday.

U.S. equities have rallied since Trump's November election, spurred by hopes for fiscal stimulus, lower taxes and fewer regulations under the Republican-led federal government.

"The market is starting to come down from its euphoric high and realize that... More